Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.

To study how virus evolution affects neutralization sensitivity and to determine changes that occur in and around epitopes, we tested the ability of 13 anti-HIV-1 gp120 (anti-V2, anti-V3, anti-CD4bd and anti-carbohydrate) human monoclonal antibodies (mAbs) to neutralize sequential viruses obtained f...

Full description

Bibliographic Details
Main Authors: Bijayesh Haldar, Sherri Burda, Constance Williams, Leo Heyndrickx, Guido Vanham, Miroslaw K Gorny, Phillipe Nyambi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-02-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3044167?pdf=render
id doaj-17a9c2ba92d245d4b19d2c1951bab99a
record_format Article
spelling doaj-17a9c2ba92d245d4b19d2c1951bab99a2020-11-24T20:52:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-02-0162e1725310.1371/journal.pone.0017253Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.Bijayesh HaldarSherri BurdaConstance WilliamsLeo HeyndrickxGuido VanhamMiroslaw K GornyPhillipe NyambiTo study how virus evolution affects neutralization sensitivity and to determine changes that occur in and around epitopes, we tested the ability of 13 anti-HIV-1 gp120 (anti-V2, anti-V3, anti-CD4bd and anti-carbohydrate) human monoclonal antibodies (mAbs) to neutralize sequential viruses obtained from five HIV-1 chronically infected drug naïve individuals. Overall, primary viruses collected from patients at first visit were resistant to neutralization by all anti-HIV-1 mAbs with the exception of one virus sensitive to IgG1b12. Four of the five patients' viruses evolved increased sensitivity to neutralization by anti-V3 mAbs. Virus collected from a patient obtained 31 months later, evolved increased sensitivity to anti-V2, anti-V3, and anti-CD4bd mAbs. Furthermore, the anti-V2 and anti-CD4bd mAbs also exhibited increased neutralization capacities against virus collected from a patient 29 months later. Of the seven anti-V3 mAbs, five showed increased potency to neutralize the evolved virus from a patient collected after 11 months, and three exhibited increased potency against viruses from two patients collected 29 and 36 months later. Anti-V3 mAbs exhibited the most breadth and potency in neutralizing the evolving viruses. Sequence analysis of the envelope regions revealed amino acid conservation within the V3 loop, while most of the changes identified occurred outside the core epitopes and in particular within the C3 region; these may account for increased neutralization sensitivity. These studies demonstrate that in vivo, HIV-1 can evolve increased neutralization sensitivity to mAbs and that the spectrum of neutralization capacities by mAbs can be broader when studied in longitudinal analysis.http://europepmc.org/articles/PMC3044167?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Bijayesh Haldar
Sherri Burda
Constance Williams
Leo Heyndrickx
Guido Vanham
Miroslaw K Gorny
Phillipe Nyambi
spellingShingle Bijayesh Haldar
Sherri Burda
Constance Williams
Leo Heyndrickx
Guido Vanham
Miroslaw K Gorny
Phillipe Nyambi
Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.
PLoS ONE
author_facet Bijayesh Haldar
Sherri Burda
Constance Williams
Leo Heyndrickx
Guido Vanham
Miroslaw K Gorny
Phillipe Nyambi
author_sort Bijayesh Haldar
title Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.
title_short Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.
title_full Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.
title_fullStr Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.
title_full_unstemmed Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.
title_sort longitudinal study of primary hiv-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-hiv-1 monoclonal antibodies.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-02-01
description To study how virus evolution affects neutralization sensitivity and to determine changes that occur in and around epitopes, we tested the ability of 13 anti-HIV-1 gp120 (anti-V2, anti-V3, anti-CD4bd and anti-carbohydrate) human monoclonal antibodies (mAbs) to neutralize sequential viruses obtained from five HIV-1 chronically infected drug naïve individuals. Overall, primary viruses collected from patients at first visit were resistant to neutralization by all anti-HIV-1 mAbs with the exception of one virus sensitive to IgG1b12. Four of the five patients' viruses evolved increased sensitivity to neutralization by anti-V3 mAbs. Virus collected from a patient obtained 31 months later, evolved increased sensitivity to anti-V2, anti-V3, and anti-CD4bd mAbs. Furthermore, the anti-V2 and anti-CD4bd mAbs also exhibited increased neutralization capacities against virus collected from a patient 29 months later. Of the seven anti-V3 mAbs, five showed increased potency to neutralize the evolved virus from a patient collected after 11 months, and three exhibited increased potency against viruses from two patients collected 29 and 36 months later. Anti-V3 mAbs exhibited the most breadth and potency in neutralizing the evolving viruses. Sequence analysis of the envelope regions revealed amino acid conservation within the V3 loop, while most of the changes identified occurred outside the core epitopes and in particular within the C3 region; these may account for increased neutralization sensitivity. These studies demonstrate that in vivo, HIV-1 can evolve increased neutralization sensitivity to mAbs and that the spectrum of neutralization capacities by mAbs can be broader when studied in longitudinal analysis.
url http://europepmc.org/articles/PMC3044167?pdf=render
work_keys_str_mv AT bijayeshhaldar longitudinalstudyofprimaryhiv1isolatesindrugnaiveindividualsrevealstheemergenceofvariantssensitivetoantihiv1monoclonalantibodies
AT sherriburda longitudinalstudyofprimaryhiv1isolatesindrugnaiveindividualsrevealstheemergenceofvariantssensitivetoantihiv1monoclonalantibodies
AT constancewilliams longitudinalstudyofprimaryhiv1isolatesindrugnaiveindividualsrevealstheemergenceofvariantssensitivetoantihiv1monoclonalantibodies
AT leoheyndrickx longitudinalstudyofprimaryhiv1isolatesindrugnaiveindividualsrevealstheemergenceofvariantssensitivetoantihiv1monoclonalantibodies
AT guidovanham longitudinalstudyofprimaryhiv1isolatesindrugnaiveindividualsrevealstheemergenceofvariantssensitivetoantihiv1monoclonalantibodies
AT miroslawkgorny longitudinalstudyofprimaryhiv1isolatesindrugnaiveindividualsrevealstheemergenceofvariantssensitivetoantihiv1monoclonalantibodies
AT phillipenyambi longitudinalstudyofprimaryhiv1isolatesindrugnaiveindividualsrevealstheemergenceofvariantssensitivetoantihiv1monoclonalantibodies
_version_ 1716799197142843392